Health Care Cost Institute Welcomes Two New Board Members

WASHINGTON (December 11, 2018) — The Health Care Cost Institute is pleased to announce the appointment of two new board members, Amy Finkelstein and Marshall Votta, to further accelerate HCCI’s vision and priorities as it enters 2019.

“We are thrilled to welcome Amy and Marshall, who are true pioneers in their respective fields. They will both diversify and complement the existing expertise of the HCCI board as we continue our role in the national conversation on health care spending,” said HCCI President Niall Brennan. “We are committed to expanding our data holdings, research and analytic impact, and business lines; and Amy and Marshall will be critical to those efforts.” 

  • Amy Finkelstein is a health economist at the Massachusetts Institute of Technology and recipient of both a 2018 MacArthur Foundation “Genius Grant” and the 2012 John Bate Clark Medal, which is awarded to the nation’s leading economist under 40. As a MacArthur Fellow, Finkelstein is exploring how health care policy affects health, health care, and well-being. She is the founding editor of the American Economic Review: Insights and co-director of the Public Economics Program at the National Bureau of Economic Research. Her research has been featured in the Journal of the American Medical AssociationNew England Journal of Medicine, and Health Affairs, and also reported on in the New York TimesWall Street Journal, and other leading news outlets.
  •  Marshall Votta is a health care entrepreneur, strategist and advisor. Votta brings 20 years of experience in provider, administrative, clinical and financial settings. He has managed strategy and growth for health care companies, including RowdMap and NaviNet, and has advised and implemented services for many of the top U.S. payers. Marshall formulates solutions that transform the relationships between health plans and providers with his expertise in technology, policy and communications.

About the Health Care Cost Institute
The Health Care Cost Institute’s mission is to get to the heart of the key issues impacting the U.S. health care system—by using the best data to get the best answers. HCCI stands for truth and consensus around the most important trends in health care, particularly those economic issues that are critical to a sustainable, high-performing health system. Launched in 2011, HCCI currently holds one of the largest databases for the commercially insured population, and in 2014 became the first national Qualified Entity (QE) entitled to hold Medicare data. For more information, visit healthcostinstitute.org or follow us on Twitter @healthcostinst.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.